CZ286202B6 - Farmaceutický přípravek - Google Patents

Farmaceutický přípravek Download PDF

Info

Publication number
CZ286202B6
CZ286202B6 CZ19941825A CZ182594A CZ286202B6 CZ 286202 B6 CZ286202 B6 CZ 286202B6 CZ 19941825 A CZ19941825 A CZ 19941825A CZ 182594 A CZ182594 A CZ 182594A CZ 286202 B6 CZ286202 B6 CZ 286202B6
Authority
CZ
Czechia
Prior art keywords
lipase
acarbose
alpha
inhibition properties
tetrahydrolipstatin
Prior art date
Application number
CZ19941825A
Other languages
Czech (cs)
English (en)
Other versions
CZ182594A3 (en
Inventor
Klaus-Dieter Bremer
Pavel Sawlewicz
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CZ182594A3 publication Critical patent/CZ182594A3/cs
Publication of CZ286202B6 publication Critical patent/CZ286202B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CZ19941825A 1993-08-05 1994-07-29 Farmaceutický přípravek CZ286202B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05

Publications (2)

Publication Number Publication Date
CZ182594A3 CZ182594A3 (en) 1995-02-15
CZ286202B6 true CZ286202B6 (cs) 2000-02-16

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19941825A CZ286202B6 (cs) 1993-08-05 1994-07-29 Farmaceutický přípravek

Country Status (24)

Country Link
US (1) US5643874A (pl)
EP (1) EP0638317B1 (pl)
JP (1) JP2780932B2 (pl)
KR (1) KR100342285B1 (pl)
CN (1) CN1076196C (pl)
AT (1) ATE190503T1 (pl)
AU (1) AU684793B2 (pl)
BR (1) BR9403170A (pl)
CA (1) CA2128044C (pl)
CZ (1) CZ286202B6 (pl)
DE (1) DE59409200D1 (pl)
DK (1) DK0638317T3 (pl)
ES (1) ES2144019T3 (pl)
GR (1) GR3033643T3 (pl)
HU (1) HU222346B1 (pl)
IL (1) IL110510A (pl)
NO (1) NO313490B1 (pl)
NZ (1) NZ264142A (pl)
PL (1) PL175997B1 (pl)
PT (1) PT638317E (pl)
RU (1) RU2141844C1 (pl)
SA (1) SA94150156B1 (pl)
TW (1) TW381025B (pl)
ZA (1) ZA945673B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298468B6 (cs) * 1997-06-23 2007-10-10 N-Gene Research Laboratories Inc. Farmaceutické prostredky se zesílenou protinádorovou aktivitou a/nebo sníženými nežádoucími úcinky obsahující protinádorové cinidlo a derivát kyseliny hydroximové

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9807655A (pt) * 1997-02-05 2000-02-15 Hoffmann La Roche Uso de inibidores de lipase gastrintestinal.
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
BR9912980B1 (pt) * 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
EP1112063A4 (en) 1998-09-08 2009-05-13 Smithkline Beecham Corp TABLETS BASED ON AN LPSTATINE DERIVATIVE AND SOLUBLE FIBERS
DE60012301D1 (de) 1999-01-22 2004-08-26 Hunza Di Pistolesi Elvira & C Lipoproteinkomplexe und zusammensetzungen, die diese enthalten
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
CA2358921A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
CN100423715C (zh) * 2000-07-28 2008-10-08 霍夫曼-拉罗奇有限公司 新型药物组合物
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
IL162323A0 (en) 2001-12-04 2005-11-20 Biogal Pharmaceutical Co Preparation of orlistat and orlistat crystalline forms
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
US20060029567A1 (en) 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20070009615A1 (en) * 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AP2008004602A0 (en) * 2006-02-23 2008-10-31 Pfizer Ltd Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP2010510201A (ja) * 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
PL2002825T3 (pl) * 2007-06-14 2013-12-31 Krka Kompozycje farmaceutyczne zawierające orlistat
EP2190303A1 (en) 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
KR20100102646A (ko) 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
CA2731897C (en) * 2008-08-06 2013-07-02 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
JP2016510306A (ja) * 2012-05-08 2016-04-07 セリックスビオ プライヴェート リミテッド 高血糖の治療のための組成物及び方法
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
UA122403C2 (uk) * 2014-12-17 2020-11-10 Емпрос Фарма Аб Композиція орлістату та акарбози з модифікованим вивільненням для лікування ожиріння і пов'язаних метаболічних порушень
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US20240226024A1 (en) * 2021-05-21 2024-07-11 Empros Pharma Ab Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarbose
WO2022243534A1 (en) * 2021-05-21 2022-11-24 Empros Pharma Ab Reduced rebound effects in subjects treated for overweight or obesity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
ZA824382B (en) * 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK520784A (da) * 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
DE68905424T2 (de) * 1988-08-22 1993-06-24 Takeda Chemical Industries Ltd Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298468B6 (cs) * 1997-06-23 2007-10-10 N-Gene Research Laboratories Inc. Farmaceutické prostredky se zesílenou protinádorovou aktivitou a/nebo sníženými nežádoucími úcinky obsahující protinádorové cinidlo a derivát kyseliny hydroximové

Also Published As

Publication number Publication date
KR950005319A (ko) 1995-03-20
RU94028653A (ru) 1996-09-10
EP0638317B1 (de) 2000-03-15
PT638317E (pt) 2000-07-31
AU684793B2 (en) 1998-01-08
DK0638317T3 (da) 2000-06-26
TW381025B (en) 2000-02-01
KR100342285B1 (ko) 2002-10-25
CA2128044C (en) 2007-02-20
PL304557A1 (en) 1995-02-06
CN1106701A (zh) 1995-08-16
GR3033643T3 (en) 2000-10-31
NZ264142A (en) 1996-11-26
PL175997B1 (pl) 1999-03-31
JP2780932B2 (ja) 1998-07-30
RU2141844C1 (ru) 1999-11-27
EP0638317A1 (de) 1995-02-15
CN1076196C (zh) 2001-12-19
SA94150156B1 (ar) 2005-05-15
NO942900D0 (pl) 1994-08-04
US5643874A (en) 1997-07-01
ZA945673B (en) 1995-02-07
NO313490B1 (no) 2002-10-14
AU6883994A (en) 1995-02-16
HU9402249D0 (en) 1994-09-28
JPH0753409A (ja) 1995-02-28
BR9403170A (pt) 1995-04-18
ES2144019T3 (es) 2000-06-01
IL110510A0 (en) 1994-11-11
CA2128044A1 (en) 1995-02-06
ATE190503T1 (de) 2000-04-15
IL110510A (en) 1999-03-12
DE59409200D1 (de) 2000-04-20
NO942900L (no) 1995-02-06
CZ182594A3 (en) 1995-02-15
HU222346B1 (hu) 2003-06-28
HUT68300A (en) 1995-06-28

Similar Documents

Publication Publication Date Title
RU2141844C1 (ru) Фармацевтическое соединение
Pearson et al. Niclosamide therapy for tapeworm infections
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
DK170922B1 (da) Cefaclorformulering med langvarig virkning
RU2116071C1 (ru) Лекарственные препараты, набор и способ лечения желудочно-кишечных заболеваний, вызываемых или опосредуемых заражением helicobaeter pylori
HU224592B1 (hu) Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmény előállítására
EP0629400B1 (en) Idebenone compositions for treating Alzheimer's disease
CA2382887A1 (en) Immunopotentiating compositions
CN1095366C (zh) N－乙酰－d－氨基葡萄糖在制备治疗肠道疾病药物中的应用
WO2019070478A1 (en) USE OF A BENZOATE-CONTAINING COMPOSITION FOR TREATING GLYCINIC ENCEPHALOPATHY
US3764672A (en) Composition and process of treatment using lincomycin derivatives
US20080038336A1 (en) Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent
NL8105635A (nl) Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
US3996356A (en) Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
CN103263425B (zh) 磷霉素氨丁三醇在制备治疗慢性细菌性前列腺炎药物中的应用
HU222835B1 (hu) Amino-purin antivírusos szerek alkalmazása latens herpeszvírus-fertőzés kezelésére és megelőzésére szolgáló gyógyszerkészítmények hatóanyagaként
US3940481A (en) Treatment of hepatic coma with isomaltitol
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
NZ529895A (en) Laxative preparation
RU2304439C1 (ru) Лекарственное средство и способ лечения сахарного диабета
CN114796252A (zh) 一类罗红霉素和西米替丁的复方制剂及制备方法
Feo et al. Evaluation of tritheon (aminitrozole) in male trichomoniasis
RU2026673C1 (ru) Средство для лечения энуреза
JP2002265354A (ja) 抗ピロリ菌剤組成物
PT100729A (pt) Processo para a preparacao de um medicamento contendo subsalicilato de bismuto para tratamento antimicrobiano

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20140729